These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 12920019

  • 1. Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
    Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C, Chauncey TR, Doney K, Georges GE, Kiem HP, Martin PJ, Petersdorf EW, Radich J, Sanders JE, Sandmaier BM, Warren EH, Witherspoon RP, Storb R, Appelbaum FR.
    Blood; 2003 Dec 01; 102(12):3912-8. PubMed ID: 12920019
    [Abstract] [Full Text] [Related]

  • 2. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia.
    Kerbauy DM, Gooley TA, Sale GE, Flowers ME, Doney KC, Georges GE, Greene JE, Linenberger M, Petersdorf E, Sandmaier BM, Scott BL, Sorror M, Stirewalt DL, Stewart FM, Witherspoon RP, Storb R, Appelbaum FR, Deeg HJ.
    Biol Blood Marrow Transplant; 2007 Mar 01; 13(3):355-65. PubMed ID: 17317589
    [Abstract] [Full Text] [Related]

  • 3. Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.
    Gagelmann N, Eikema DJ, de Wreede LC, Koster L, Wolschke C, Arnold R, Kanz L, McQuaker G, Marchand T, Socié G, Bourhis JH, Mohty M, Cornelissen JJ, Chevallier P, Bernasconi P, Stelljes M, Rohrlich PS, Fanin R, Finke J, Maertens J, Blaise D, Itälä-Remes M, Labussière-Wallet H, Robin M, McLornan D, Chalandon Y, Yakoub-Agha I, Kröger N, CMWP of the European Society for Blood and Marrow Transplantation.
    Biol Blood Marrow Transplant; 2019 Jun 01; 25(6):e204-e208. PubMed ID: 30930192
    [Abstract] [Full Text] [Related]

  • 4. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
    Lussana F, Rambaldi A, Finazzi MC, van Biezen A, Scholten M, Oldani E, Carobbio A, Iacobelli S, Finke J, Nagler A, Volin L, Lamy T, Arnold R, Mohty M, Michallet M, de Witte T, Olavarria E, Kröger N.
    Haematologica; 2014 May 01; 99(5):916-21. PubMed ID: 24389309
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR.
    Bone Marrow Transplant; 2000 Oct 01; 26(7):711-6. PubMed ID: 11042650
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis.
    Anderson JE, Sale G, Appelbaum FR, Chauncey TR, Storb R.
    Br J Haematol; 1997 Sep 01; 98(4):1010-6. PubMed ID: 9326205
    [Abstract] [Full Text] [Related]

  • 11. Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia.
    Ballen KK, Woolfrey AE, Zhu X, Ahn KW, Wirk B, Arora M, George B, Savani BN, Bolwell B, Porter DL, Copelan E, Hale G, Schouten HC, Lewis I, Cahn JY, Halter J, Cortes J, Kalaycio ME, Antin J, Aljurf MD, Carabasi MH, Hamadani M, McCarthy P, Pavletic S, Gupta V, Deeg HJ, Maziarz RT, Horowitz MM, Saber W.
    Biol Blood Marrow Transplant; 2012 Sep 01; 18(9):1446-54. PubMed ID: 22449610
    [Abstract] [Full Text] [Related]

  • 12. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.
    Rondelli D, Goldberg JD, Isola L, Price LS, Shore TB, Boyer M, Bacigalupo A, Rambaldi A, Scarano M, Klisovic RB, Gupta V, Andreasson B, Mascarenhas J, Wetzler M, Vannucchi AM, Prchal JT, Najfeld V, Orazi A, Weinberg RS, Miller C, Barosi G, Silverman LR, Prosperini G, Marchioli R, Hoffman R.
    Blood; 2014 Aug 14; 124(7):1183-91. PubMed ID: 24963042
    [Abstract] [Full Text] [Related]

  • 13. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia.
    Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP, Spivak JL, Smith BD, Klingemann HG, Fruchtman S, Hoffman R, Myeloproliferative Diseases-Research Consortium.
    Blood; 2005 May 15; 105(10):4115-9. PubMed ID: 15671439
    [Abstract] [Full Text] [Related]

  • 14. Outcome of transplantation for myelofibrosis.
    Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ, Cervantes F, Devine SM, Gale RP, Gupta V, Hahn TE, Hogan WJ, Kröger N, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Schiller G, Schouten HC, Roy V, Wiernik PH, Horowitz MM, Giralt SA, Arora M.
    Biol Blood Marrow Transplant; 2010 Mar 15; 16(3):358-67. PubMed ID: 19879949
    [Abstract] [Full Text] [Related]

  • 15. Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation.
    Raj K, Eikema DJ, McLornan DP, Olavarria E, Blok HJ, Bregante S, Ciceri F, Passweg J, Ljungman P, Schaap N, Carlson K, Zuckerman T, de Wreede LC, Volin L, Koc Y, Diez-Martin JL, Brossart P, Wolf D, Blaise D, Bartolomeo PD, Vitek A, Robin M, Yakoub-Agha I, Chalandon Y, Kroger N.
    Biol Blood Marrow Transplant; 2019 Mar 15; 25(3):522-528. PubMed ID: 30408564
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age.
    Samuelson S, Sandmaier BM, Heslop HE, Popat U, Carrum G, Champlin RE, Storb R, Prchal JT, Gooley TA, Deeg HJ.
    Br J Haematol; 2011 Apr 15; 153(1):76-82. PubMed ID: 21323890
    [Abstract] [Full Text] [Related]

  • 18. Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience.
    Zaidman I, Rowe JM, Khalil A, Ben-Arush M, Elhasid R.
    Biol Blood Marrow Transplant; 2016 Jun 15; 22(6):1043-1048. PubMed ID: 27016193
    [Abstract] [Full Text] [Related]

  • 19. [Umbilical cord blood cell transplantation from an unrelated donor: dual transplantation].
    Bautista G, Regidor C, Gonzalo-Daganzo R, Cabrera JR.
    Methods Find Exp Clin Pharmacol; 2010 Dec 15; 32 Suppl A():47-51. PubMed ID: 21381288
    [Abstract] [Full Text] [Related]

  • 20. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
    Kröger N, Thiele J, Zander A, Schwerdtfeger R, Kobbe G, Bornhäuser M, Bethge W, Schubert J, de Witte T, Kvasnicka HM, MDS-Subcommittee of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation.
    Exp Hematol; 2007 Nov 15; 35(11):1719-22. PubMed ID: 17976523
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.